MarketWatchCenter·
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Read at MarketWatch →
Markets · 1 sources covering this
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/f5831197df7dff8b915db7b68009f65205701aa3" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying."></iframe>
